Literature DB >> 19434631

Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy.

Srinivasan Shanmugarajan1, Eichi Tsuruga, Kathryn J Swoboda, Bernard L Maria, William L Ries, Sakamuri V Reddy.   

Abstract

Spinal muscular atrophy (SMA) is characterized by degenerating lower motor neurons and an increased incidence of congenital bone fractures. Survival motor neuron (SMN) levels are significantly reduced due to deletions/mutations in the telomeric SMN1 gene in these patients. We utilized the Smn(-/-) SMN2 mouse model of SMA to determine the functional role for SMN in bone remodelling. microCT analysis of lumber vertebrae, tibia and femur bones from SMA mice revealed an osteoporotic bone phenotype. Histological analysis demonstrated a thin porous cortex of cortical bone and thin trabeculae at the proximal end of the growth plate in the vertebrae of SMA mice compared to wild-type mice. Histochemical staining of the vertebrae showed the presence of abundant activated osteoclasts on the sparse trabeculae and on the endosteal surface of the thin cortex in SMA mice. Histomorphometric analysis of vertebrae from SMA mice showed an increased number of osteoclasts. Serum TRAcP5b and urinary NTx levels were elevated, consistent with increased bone resorption in these mice. SMA mice showed a significant decrease in the levels of osteoblast differentiation markers, osteocalcin, osteopontin and osterix mRNA expression; however, there were no change in the levels of alkaline phosphatase expression compared to WT mice. SMA mouse bone marrow cultures revealed an increased rate of osteoclast formation (54%) and bone resorption capacity (46%) compared to WT mice. Pre-osteoclast cells from SMA mice showed constitutive up-regulation of RANK receptor signalling molecules critical for osteoclast differentiation. Our results implicate SMN function in bone remodelling and skeletal pathogenesis in SMA. Understanding basic mechanisms of SMN action in bone remodelling may uncover new therapeutic targets for preventing bone loss/fracture risk in SMA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434631      PMCID: PMC2791336          DOI: 10.1002/path.2566

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

Authors:  B Schrank; R Götz; J M Gunnersen; J M Ure; K V Toyka; A G Smith; M Sendtner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  SMN oligomerization defect correlates with spinal muscular atrophy severity.

Authors:  C L Lorson; J Strasswimmer; J M Yao; J D Baleja; E Hahnen; B Wirth; T Le; A H Burghes; E J Androphy
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

3.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

4.  Osteoclast-stimulating factor interacts with the spinal muscular atrophy gene product to stimulate osteoclast formation.

Authors:  N Kurihara; C Menaa; H Maeda; D J Haile; S V Reddy
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

5.  Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy.

Authors:  H Iwahashi; Y Eguchi; N Yasuhara; T Hanafusa; Y Matsuzawa; Y Tsujimoto
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

6.  Identification and characterization of a mouse homologue of the spinal muscular atrophy-determining gene, survival motor neuron.

Authors:  A Bergin; G Kim; D L Price; S S Sisodia; M K Lee; B A Rabin
Journal:  Gene       Date:  1997-12-19       Impact factor: 3.688

7.  Identification of the functional domain of osteoclast inhibitory peptide-1/hSca.

Authors:  Masanori Koide; Noriyoshi Kurihara; Hidefumi Maeda; Sakamuri V Reddy
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

8.  CytokineRegulation and the signaling mechanism of osteoclast inhibitory peptide-1 (OIP-1/hSca) to inhibit osteoclast formation.

Authors:  Masanori Koide; Hidefumi Maeda; Jennifer L Roccisana; Noriaki Kawanabe; Sakamuri V Reddy
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

9.  Hypercalcaemia in infancy; a presenting feature of spinal muscular atrophy.

Authors:  K Khawaja; W T Houlsby; S Watson; K Bushby; T Cheetham
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

10.  Severe spinal muscular atrophy variant associated with congenital bone fractures.

Authors:  Ursula Felderhoff-Mueser; Katja Grohmann; Anja Harder; Christine Stadelmann; Klaus Zerres; Christoph Bührer; Michael Obladen
Journal:  J Child Neurol       Date:  2002-09       Impact factor: 1.987

View more
  26 in total

1.  Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction.

Authors:  Rocky G Gogliotti; Katharina A Quinlan; Courtenay B Barlow; Christopher R Heier; C J Heckman; Christine J Didonato
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

Review 2.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

Review 3.  How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.

Authors:  N N Singh; M D Howell; E J Androphy; R N Singh
Journal:  Gene Ther       Date:  2017-05-09       Impact factor: 5.250

Review 4.  A survey of transcripts generated by spinal muscular atrophy genes.

Authors:  Natalia N Singh; Eric W Ottesen; Ravindra N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-05-06       Impact factor: 4.490

5.  Mutations in the survival motor neuron (SMN) protein alter the dynamic nature of nuclear bodies.

Authors:  Robert Morse; Adrian G Todd; Debra J Shaw; Alison L McConville; Iain M Robinson; Philip J Young
Journal:  Neuromolecular Med       Date:  2010-11-17       Impact factor: 3.843

Review 6.  The Genetics of Spinal Muscular Atrophy: Progress and Challenges.

Authors:  Michelle A Farrar; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings.

Authors:  Rebecca Hurst Davis; Barbara J Godshall; Erin Seffrood; Mary Marcus; Bernard A LaSalle; Brenda Wong; Mary K Schroth; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-10-04       Impact factor: 1.987

8.  Vitamin D intake is inadequate in spinal muscular atrophy type I cohort: correlations with bone health.

Authors:  Jennifer Aton; Rebecca Hurst Davis; Kristine C Jordan; Charles B Scott; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-01-17       Impact factor: 1.987

9.  Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I.

Authors:  Katherine E Poruk; Rebecca Hurst Davis; Abby L Smart; Benjamin S Chisum; Bernie A Lasalle; Gary M Chan; Gurmail Gill; Sandra P Reyna; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2012-07-23       Impact factor: 4.296

10.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy.

Authors:  N Nasomyont; L N Hornung; H Wasserman
Journal:  Osteoporos Int       Date:  2019-12-02       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.